Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN026 plus chemotherapy versus placebo plus chemotherapy after first-line failure in HER2-positive gastric or gastroesophageal junction adenocarcinoma
CTR20213458Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Apr 2022; status: active.
02
Drugs
anbenitamab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20213458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213458.